AnaptysBio, Inc. ANAB Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by AnaptysBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about AnaptysBio, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AnaptysBio, Inc.'s cash & equivalents?
- AnaptysBio, Inc. (ANAB) reported cash & equivalents of $248.47M in Q1 2026.
- How has AnaptysBio, Inc.'s cash & equivalents changed year-over-year?
- AnaptysBio, Inc.'s cash & equivalents increased by 151.9% year-over-year, from $98.64M to $248.47M.
- What is the long-term trend for AnaptysBio, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), AnaptysBio, Inc.'s cash & equivalents has grown at a -1.0% compound annual growth rate (CAGR), from $250.46M to $238.2M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.